Foresite Capital Management IV, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001704132

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 6 positions · Total reported value $252.03M · Top-10 concentration 100.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 28.6% · 1 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Foresite Capital Management IV, LLC disclosed 6 equity positions with a combined reported value of $252.03M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PHVS ($151.58M), CYTK ($47.11M), RLAY ($22.56M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+1.9pp) and away from Other (-1.9pp).

Versus the prior quarter, Foresite Capital Management IV, LLC opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 28.6% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q3 2026 were VCYT ($9.21M).

Of the 1 positions fully exited versus the prior quarter, the largest were CRNX ($5.61M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VCYT VERACYTE INC · $9.21M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $5.61M

Insider Transactions (Form 4)

Latest Foresite Capital Management IV, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Foresite Capital Management IV, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 6 positions worth $252.03M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 6 positions · $252.03M reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: PHVS (PHARVARIS N V) at 60.1%
  • Average position size: $42.01M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 1 new, 1 exited
  • 5 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintained a concentrated, healthcare-focused portfolio with no sales (all holds/new), suggesting a bullish stance on biotech/therapeutics but no major tactical shifts. 2. Key moves: Added VCYT (3.65% weight, new position); no reductions (all holds). No sales, indicating conviction in existing holdings. 3. Portfolio structure: Highly active, concentrated (top 6 holdings = 100%), and deeply biased toward Health Care (biotech/therapeutics). High risk appetite due to small-cap, clinical-stage companies. 4. Per-holding one-liner: - PHVS: PHARVARIS N V (unverified, likely enzyme therapeutics). - CYTK: CYTOKINETICS INC (unverified, likely muscle/heart disease drugs). - RLAY: RELAY THERAPEUTICS INC (unverified, likely targeted cancer therapies). - EIKN: EIKON THERAPEUTICS INC (unverified, likely GPCR-focused drugs). - VCYT: VERACYTE INC (unverified, likely diagnostic tests). - XENE: XENON PHARMACEUTICALS INC (unverified, likely pain/nerve disorder drugs). 5. Style summary: Concentrated, healthcare-dedicated fund with no sales, adding a new diagnostic play while holding biotech/therapeutics through clinical-stage catalysts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 13:22

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.78M $151.58M 60.14%
60.14%
Hold
2 714.70K $47.11M 18.69%
18.69%
Hold
3 1.25M $22.56M 8.95%
8.95%
Hold
4 1.94M $15.63M 6.20%
6.20%
Hold
5 200.00K $9.21M 3.65%
3.65%
New
6 160.00K $5.95M 2.36%
2.36%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 83% R 83% F1 83% (modelled on 2026-Q2; 5/10 hit)

Historical Backtest (11 quarters)

Avg precision 90% · recall 88% · F1 88% · avg rank error 1.7 · Top-10 turnover 12%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 100% 100% PHVS · KURA · KNTE · SNDX · LYEL PHVS · KURA · KNTE · SNDX · LYEL
2024-Q2 80% 100% 89% PHVS · KURA · KNTE · SNDX · LYEL PHVS · KURA · SNDX · LYEL
2024-Q3 100% 80% 89% PHVS · KURA · SNDX · LYEL PHVS · KURA · SNDX · LYEL · RLAY
2024-Q4 80% 100% 89% PHVS · KURA · SNDX · LYEL · RLAY PHVS · KURA · LYEL · RLAY
2025-Q1 100% 80% 89% PHVS · KURA · LYEL · RLAY PHVS · MAZE · LYEL · KURA · RLAY
2025-Q2 100% 83% 91% PHVS · MAZE · LYEL · KURA · RLAY PHVS · MAZE · LYEL · XENE · KURA · RLAY
2025-Q3 83% 83% 83% PHVS · MAZE · LYEL · XENE · KURA · RLAY PHVS · CYTK · MAZE · LYEL · XENE · RLAY
2025-Q4 100% 86% 92% PHVS · CYTK · MAZE · LYEL · XENE · RLAY PHVS · CYTK · LYEL · MAZE · RLAY · XENE · ALEC
2026-Q1 100% 88% 93% PHVS · CYTK · LYEL · MAZE · RLAY · XENE · ALEC PHVS · CYTK · EIKN · LYEL · RLAY · XENE · ALEC · MAZE
2026-Q2 62% 83% 71% PHVS · CYTK · EIKN · LYEL · RLAY · XENE · ALEC · MAZE PHVS · CYTK · EIKN · RLAY · XENE · CRNX
2026-Q3 ★ 83% 83% 83% PHVS · CYTK · EIKN · RLAY · XENE · CRNX PHVS · CYTK · RLAY · EIKN · VCYT · XENE

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings1 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-4.32%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+12.69%vs benchmark
Barra annualised vol82.2%Model estimate
Realised vol72.0%Annualised in window
Weighted beta1.52Raw exposure
Factor / specific risk35% / 65%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.687.196.6106.1115.610-0110-2311-16Foresite Capital Management IV, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-4.32%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+12.69%Portfolio − benchmark
Arithmetic return sum-1.13%Difference vs compounded is the cross term
Weighted raw beta1.52Weighted holding betas
Realised volatility (annualised)72.01%Daily returns in window
Barra model volatility (annualised)82.18%Factor + specific
Factor share of variance34.9%Barra factors
Specific share of variance65.1%Stock residuals
Reported value$22.6M13F long US equity

2. Return attribution

The -1.13% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -2.59% -228.5%
Momentum & Growth 3 -16.81% -1485.3%
Volatility & Tail Risk 7 +3.79% 334.6%
Industry 12 +6.98% 617.0%
Specific 1 +7.50% 662.2%
Return attribution (style + industry, %)-16.7-8.4+0.0+8.4+16.7Short-term Reversal+0.83Leverage (Downside Vol)-1.00Amihud Illiquidity-1.23Growth-2.14Beta+3.00Non-linear Size+3.10Turnover-3.13Size+3.23Historical Volatility-3.26Kurtosis-4.04Mid Cap-5.17Health Care+6.98Residual Volatility+8.95Momentum-15.50
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.72 +3.29% +8.95% 790.9%
Specific Specific — — +7.50% 662.2%
Health Care Industry +1.00 +6.98% +6.98% 617.0%
Size Style -1.66 -1.95% +3.23% 285.5%
Non-linear Size Style +3.07 +1.01% +3.10% 273.7%
Beta Style +0.68 +4.44% +3.00% 265.3%
Short-term Reversal Style +0.95 +0.87% +0.83% 73.3%
Skewness Style -0.16 -4.39% +0.72% 63.3%
Liquidity Style +1.71 +0.36% +0.61% 53.8%
Max Drawdown Style +0.33 -1.76% -0.59% -51.8%
Leverage (Downside Vol) Style +0.58 -1.71% -1.00% -88.2%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -108.3%
Growth Style -1.23 +1.75% -2.14% -189.4%
Turnover Style +0.65 -4.80% -3.13% -276.5%
Historical Volatility Style +0.23 -14.00% -3.26% -287.7%
Kurtosis Style -0.54 +7.51% -4.04% -357.1%
Mid Cap Style +2.67 -1.94% -5.17% -456.7%
Momentum Style +3.87 -4.00% -15.50% -1369.2%

3. Risk attribution

Annualised volatility is 82.18%; factor risk explains 34.9% of variance and specific risk 65.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-70.3-35.1+0.0+35.1+70.3Growth-1.87Non-linear Size-0.49Turnover+0.22Max Drawdown+0.31Short-term Reversal+0.97Amihud Illiquidity+1.22Liquidity+2.49Size+2.51Beta+3.12Mid Cap+3.80Health Care+4.37Residual Volatility+4.91Momentum+13.44Specific+65.08
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 65.1% +53.48% 53.5%
Momentum Style +3.87 13.4% +11.04% 11.0%
Residual Volatility Style +2.72 4.9% +4.04% 4.0%
Health Care Industry +1.00 4.4% +3.59% 3.6%
Mid Cap Style +2.67 3.8% +3.12% 3.1%
Beta Style +0.68 3.1% +2.57% 2.6%
Size Style -1.66 2.5% +2.06% 2.1%
Liquidity Style +1.71 2.5% +2.05% 2.0%
Amihud Illiquidity Style +2.75 1.2% +1.00% 1.0%
Short-term Reversal Style +0.95 1.0% +0.80% 0.8%
Max Drawdown Style +0.33 0.3% +0.25% 0.2%
Turnover Style +0.65 0.2% +0.18% 0.2%
Non-linear Size Style +3.07 -0.5% -0.40% -0.4%
Growth Style -1.23 -1.9% -1.54% -1.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.2-0.61.12.84.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.68 +1.29 -0.62
Momentum +3.88 +0.72 +3.16
Short-term Reversal +0.95 -0.64 +1.59
Residual Volatility +2.72 -0.40 +3.12
Historical Volatility +0.23 +0.86 -0.63
Liquidity +1.71 +0.11 +1.59
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +0.65 +0.21 +0.45
Growth -1.23 +0.58 -1.81
Leverage (Downside Vol) +0.58 +0.14 +0.44
Skewness -0.16 +0.24 -0.40
Kurtosis -0.54 +0.21 -0.75
Max Drawdown +0.33 -0.08 +0.42

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -4.32% +8.29% +24.98% -0.22% -12.39% -4.46%
Total +23.98% +15.62% -28.23% +11.38%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
RLAY RELAY THERAPEUTICS INC Health Care 100.00% -4.32% -4.32% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 RLAY Health Care 100.00% -4.32% -4.32%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -4.32%, versus -17.01% for the QQQ synthetic benchmark — an excess of +12.69%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.95%, Health Care +6.98%, Size +3.23%; the largest drags came from Momentum -15.50%, Mid Cap -5.17%, Kurtosis -4.04%. Specific (stock-level) return contributed +7.50%.
  3. Risk attribution: Barra model volatility is 82.18% annualised; factor risk explains 35% of variance and specific risk 65%. The largest factor risk sources are Momentum 13.4%, Residual Volatility 4.9%, Health Care 4.4%.
  4. Style tilt: size -1.66, momentum +3.88, volatility +0.23, liquidity +1.71; the weighted raw beta is 1.52. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.62% and interaction -28.23%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Foresite Capital Management IV, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Foresite Capital Management IV, LLC reported 6 equity positions worth $252.03M in aggregate; its largest disclosed positions were PHVS ($151.58M), CYTK ($47.11M), RLAY ($22.56M).

How large is Foresite Capital Management IV, LLC's portfolio?

Foresite Capital Management IV, LLC reported $252.03M of long equity holdings across 6 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Foresite Capital Management IV, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/foresite-capital-management-iv/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →